{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:45:38Z","timestamp":1794037538178,"version":"4.8.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":93,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["2020YJZX0205"],"award-info":[{"award-number":["2020YJZX0205"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-angiogenic therapy, particularly small-molecule inhibitors targeting the vascular endothelial growth factor receptor (VEGFR), has emerged as a promising approach for treating bone and soft tissue sarcomas. This study aimed to systematically compare the efficacy and safety of different small-molecule anti-angiogenic agents in the treatment of bone and soft tissue sarcomas through a network meta-analysis (NMA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a comprehensive search of seven major databases, including China National Knowledge Infrastructure (CNKI), Wanfang, VIP Database (VIP), PubMed, Embase, Cochrane Library, and Web of Science, to collect clinical randomized controlled trials (RCTs) evaluating the use of small-molecule anti-angiogenic drugs in the treatment of bone and soft tissue tumors. R softwarewas used for data analysis. We combined all direct and indirect evidence to compare different treatments in terms of efficacy and safety, reported as hazard ratio (HR) for survival outcomes (progression-free survival and overall survival) and odds ratio (OR) for binary outcomes (objective response rate and disease control rate), with 95% confidence intervals (CIs). The P score was used to rank the side effect risk. This project has been registered on PROSPERO CRD42024584746.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The initial search yielded 946 records, and 16 studies, involving 1,291 patients, met all criteria. In terms of the disease control rate (DCR), apatinib\u2009+\u2009chemotherapy is better than chemotherapy alone (OR 0.13 (0.02, 0.92)). In terms of objective response rate (ORR), apatinib\u2009+\u2009chemo is better than pazopanib\u2009+\u2009chemotherapy (OR 0.15 (0.02, 0.94)), anlotinib is better than chemo (OR 0.26 (0.07, 0.92)) and pazopanib\u2009+\u2009chemo (OR 0.15 (0.03, 0.85)). The side effects of different treatments vary.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Short-term efficacy of small-molecule anti-angiogenic TKIs varied across bone and soft tissue sarcomas, with trends favoring apatinib plus chemotherapy and anlotinib. However, substantial heterogeneity across studies, including sarcoma subtypes and prior therapies, limits definitive\u00a0conclusions regarding comparative efficacy. A multidisciplinary team is needed to better manage the side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-15412-1","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T10:37:20Z","timestamp":1765363040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety comparison of small molecule anti-angiogenic drugs in the treatment of bone and soft tissue sarcomas : a network meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Jianping","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xincai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"issue":"2","key":"15412_CR1","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/ijc.34694","volume":"154","author":"Y Xu","year":"2024","unstructured":"Xu Y, Shi F, Zhang Y, et al. <article-title update=\"added\">Twenty\u2010year outcome of prevalence, incidence, mortality and survival rate in patients with malignant bone tumors. Int J Cancer. 2024;154(2):226\u201340.","journal-title":"Int J Cancer"},{"issue":"6","key":"15412_CR2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1200\/JCO.23.01275","volume":"42","author":"AR Weiss","year":"2023","unstructured":"Weiss AR, Harrison DJ. Soft tissue sarcomas in adolescents and young adults. J Clin Oncol. 2023;42(6):675\u201385.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"15412_CR3","doi-asserted-by":"publisher","first-page":"e23560","DOI":"10.1200\/JCO.2018.36.15_suppl.e23560","volume":"36","author":"R Zheng","year":"2018","unstructured":"Zheng R, Zhang S, Zeng H, et al. Incidence of soft tissue sarcoma in China. J Clin Oncol. 2018;36(15_suppl):e23560\u2013e23560.","journal-title":"J Clin Oncol"},{"issue":"1","key":"15412_CR4","first-page":"7","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"15412_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40520-024-02926-0","volume":"37","author":"X Zhang","year":"2025","unstructured":"Zhang X, Dai X, Chen Y, et al. Global, regional, and national burden of malignant neoplasm of bone and articular cartilage in adults aged 65 years and older, 1990\u20132021: a systematic analysis based on the global burden of disease study 2021. Aging Clin Exp Res. 2025;37(1):21.","journal-title":"Aging Clin Exp Res"},{"issue":"3","key":"15412_CR6","first-page":"200","volume":"70","author":"AC Gamboa","year":"2020","unstructured":"Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine. CA Cancer J Clin. 2020;70(3):200\u201329.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"15412_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11864-019-0606-9","volume":"20","author":"M Meyer","year":"2019","unstructured":"Meyer M, Seetharam M. First-line therapy for metastatic soft tissue sarcoma. Curr Treat Options Oncol. 2019;20(1):1\u201314.","journal-title":"Curr Treat Options Oncol"},{"issue":"10","key":"15412_CR8","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41571-021-00519-8","volume":"18","author":"J Gill","year":"2021","unstructured":"Gill J, Gorlick R. Advancing therapy for osteosarcoma. Nat Rev Clin Oncol. 2021;18(10):609\u201324.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10043","key":"15412_CR9","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","volume":"388","author":"GC Jayson","year":"2016","unstructured":"Jayson GC, Kerbel R, Ellis LM, et al. Antiangiogenic therapy in oncology: current status and future directions. Lancet. 2016;388(10043):518\u201329.","journal-title":"Lancet"},{"issue":"1","key":"15412_CR10","first-page":"1","volume":"8","author":"ZL Liu","year":"2023","unstructured":"Liu ZL, Chen HH, Zheng LL, Harris AL. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023;8(1):1\u201339.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"15412_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","volume":"29","author":"SA Patel","year":"2023","unstructured":"Patel SA, Nilsson MB, Le X, Cascone T, Jain RK, Heymach JV. Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy. Clin Cancer Res. 2023;29(1):30\u20139.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"15412_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13102","volume":"54","author":"Y Liu","year":"2021","unstructured":"Liu Y, Huang N, Liao S, Rothzerg E, Yao F, Li Y, et al. Current research progress in targeted anti-angiogenesis therapy for osteosarcoma. Cell Prolif. 2021;54(9):e13102.","journal-title":"Cell Prolif"},{"issue":"31","key":"15412_CR13","first-page":"2405","volume":"102","author":"L Fan","year":"2022","unstructured":"Fan L, Ye T, Chen J. Current status and prospects of anti-angiogenic small-molecule tyrosine kinase inhibitors in the therapy of soft tissue sarcoma. Zhonghua Yi Xue Za Zhi. 2022;102(31):2405\u201310.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"15412_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ejca.2017.06.015","volume":"83","author":"JC Chisholm","year":"2017","unstructured":"Chisholm JC, Merks JHM, Casanova M, et al. Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). Eur J Cancer. 2017;83:177\u201384.","journal-title":"Eur J Cancer"},{"issue":"9829","key":"15412_CR15","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT Van der Graaf","year":"2012","unstructured":"Van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879\u201386.","journal-title":"Lancet"},{"issue":"1","key":"15412_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","volume":"20","author":"F Duffaud","year":"2019","unstructured":"Duffaud F, Mir O, Boudou-Rouquette P, et al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2019;20(1):120\u201333.","journal-title":"Lancet Oncol"},{"key":"15412_CR17","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2021.03.039","volume":"150","author":"F Duffaud","year":"2021","unstructured":"Duffaud F, Italiano A, Bompas E, et al. Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. Eur J Cancer. 2021;150:108\u201318.","journal-title":"Eur J Cancer"},{"issue":"3","key":"15412_CR18","doi-asserted-by":"publisher","first-page":"101569","DOI":"10.1016\/j.esmoop.2023.101569","volume":"8","author":"A Le Cesne","year":"2023","unstructured":"Le Cesne A, Chevreau C, Perrin C, et al. Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study. ESMO Open. 2023;8(3):101569.","journal-title":"ESMO Open"},{"issue":"16","key":"15412_CR19","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1200\/JCO.18.02374","volume":"37","author":"LE Davis","year":"2019","unstructured":"Davis LE, Bolejack V, Ryan CW, et al. Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma. JCO. 2019;37(16):1424\u201331.","journal-title":"JCO"},{"issue":"12","key":"15412_CR20","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1038\/s41416-023-02413-9","volume":"129","author":"F Duffaud","year":"2023","unstructured":"Duffaud F, Blay J-Y, Le Cesne A, et al. Regorafenib in patients with advanced ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study. Br J Cancer. 2023;129(12):1940\u20138.","journal-title":"Br J Cancer"},{"issue":"20","key":"15412_CR21","first-page":"5","volume":"45","author":"JY Liu","year":"2018","unstructured":"Liu JY, Fan ZF, Li S, et al. Single-center data analysis of a multicenter phase IIb clinical trial of anlotinib hydrochloride capsules in advanced soft tissue sarcoma. Chin J Clin Oncol. 2018;45(20):5.","journal-title":"Chin J Clin Oncol"},{"issue":"4","key":"15412_CR22","first-page":"4","volume":"16","author":"MQ Hu","year":"2018","unstructured":"Hu MQ, Gao K. Clinical efficacy of apatinib combined with AIM regimen in the treatment of advanced soft tissue sarcoma. Clin Drug Investig. 2018;16(4):4.","journal-title":"Clin Drug Investig"},{"key":"15412_CR23","first-page":"228","volume":"11","author":"N Aheaiti","year":"2022","unstructured":"Aheaiti N, Muheteer N. Short-term efficacy and safety analysis of anlotinib in the treatment of advanced soft tissue sarcoma. Jian Kang Bi Du. 2022;11:228-229,261.","journal-title":"Jian Kang Bi Du"},{"issue":"6","key":"15412_CR24","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/cncr.33216","volume":"127","author":"N Somaiah","year":"2021","unstructured":"Somaiah N, Van Tine BA, Wahlquist AE, et al. A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft\u2010tissue sarcoma. Cancer. 2021;127(6):894\u2013904.","journal-title":"Cancer"},{"issue":"11","key":"15412_CR25","doi-asserted-by":"publisher","first-page":"e1655","DOI":"10.1634\/theoncologist.2020-0679","volume":"25","author":"RF Riedel","year":"2020","unstructured":"Riedel RF, Ballman KV, Lu Y, et al. A randomized, double-blind, placebo-controlled, phase II study of regorafenib versus placebo in advanced\/metastatic, treatment-refractory liposarcoma: results from the SARC024 study. Oncologist. 2020;25(11):e1655\u201362.","journal-title":"Oncologist"},{"key":"15412_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2019.12.001","volume":"126","author":"N Penel","year":"2020","unstructured":"Penel N, Mir O, Wallet J, et al. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. Eur J Cancer. 2020;126:45\u201355.","journal-title":"Eur J Cancer"},{"issue":"3","key":"15412_CR27","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10637-009-9367-9","volume":"29","author":"S Pacey","year":"2011","unstructured":"Pacey S, Ratain MJ, Flaherty KT, et al. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a phase II randomized discontinuation trial. Invest New Drugs. 2011;29(3):481\u20138.","journal-title":"Invest New Drugs"},{"issue":"12","key":"15412_CR28","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/S1470-2045(16)30507-1","volume":"17","author":"O Mir","year":"2016","unstructured":"Mir O, Brodowicz T, Italiano A, et al. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17(12):1732\u201342.","journal-title":"Lancet Oncol"},{"issue":"30","key":"15412_CR29","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1200\/JCO.20.00714","volume":"38","author":"V Gr\u00fcnwald","year":"2020","unstructured":"Gr\u00fcnwald V, Karch A, Schuler M, et al. Randomized comparison of pazopanib and doxorubicin as first-line treatment in patients with metastatic soft tissue sarcoma age 60 years or older: results of a German intergroup study. JCO. 2020;38(30):3555\u201364.","journal-title":"JCO"},{"key":"15412_CR30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejca.2018.05.008","volume":"99","author":"T Brodowicz","year":"2018","unstructured":"Brodowicz T, Mir O, Wallet J, et al. Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. Eur J Cancer. 2018;99:28\u201336.","journal-title":"Eur J Cancer"},{"issue":"5","key":"15412_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112437","volume":"42","author":"Q Luo","year":"2023","unstructured":"Luo Q, Dong Z, Xie W, et al. Apatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy. Cell Rep. 2023;42(5):112437.","journal-title":"Cell Rep"},{"issue":"6","key":"15412_CR32","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1111\/bcp.15665","volume":"89","author":"XM Yang","year":"2023","unstructured":"Yang XM, Ye PP, Liu XL, et al. Population pharmacokinetics and pharmacogenetics of apatinib in adult cancer patients. Br J Clin Pharmacol. 2023;89(6):1862\u201372.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"15412_CR33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","volume":"9","author":"Y Sun","year":"2016","unstructured":"Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9(1):105.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"15412_CR34","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1007\/s10637-021-01115-4","volume":"39","author":"M Fukudo","year":"2021","unstructured":"Fukudo M, Asai K, Tani C, Miyamoto M, Ando K, Ueno N. Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes. Invest New Drugs. 2021;39(5):1422\u201331.","journal-title":"Invest New Drugs"},{"key":"15412_CR35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jconrel.2017.08.015","volume":"267","author":"G Kwak","year":"2017","unstructured":"Kwak G, Jo SD, Kim D, et al. Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles. J Control Release. 2017;267:203\u201313.","journal-title":"J Control Release"},{"issue":"6","key":"15412_CR36","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/joim.13717","volume":"294","author":"K Wallander","year":"2023","unstructured":"Wallander K, \u00d6fverholm I, Boye K, et al. Sarcoma care in the era of precision medicine. J Intern Med. 2023;294(6):690\u2013707.","journal-title":"J Intern Med"},{"issue":"4","key":"15412_CR37","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3390\/ijms19041232","volume":"19","author":"Y Itatani","year":"2018","unstructured":"Itatani Y, Kawada K, Yamamoto T, Sakai Y. Resistance to anti-angiogenic therapy in cancer-alterations to anti-VEGF pathway. Int J Mol Sci. 2018;19(4):1232.","journal-title":"Int J Mol Sci"},{"key":"15412_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100422","volume":"28","author":"FH Al-Ostoot","year":"2021","unstructured":"Al-Ostoot FH, Salah S, Khamees HA, et al. Tumor angiogenesis: current challenges and therapeutic opportunities. Cancer Treatment and Research Communications. 2021;28:100422.","journal-title":"Cancer Treatment and Research Communications"},{"issue":"6","key":"15412_CR39","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.semnephrol.2010.09.007","volume":"30","author":"ES Robinson","year":"2010","unstructured":"Robinson ES, Khankin EV, Karumanchi SA. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol. 2010;30(6):591\u2013601.","journal-title":"Semin Nephrol"},{"issue":"3","key":"15412_CR40","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1161\/HYPERTENSIONAHA.117.09275","volume":"70","author":"BC Boursiquot","year":"2017","unstructured":"Boursiquot BC, Zabor EC, Glezerman IG, et al. Hypertension and VEGF (Vascular endothelial growth Factor) receptor tyrosine kinase inhibition: effects on renal function. Hypertension. 2017;70(3):552\u20137.","journal-title":"Hypertension"},{"issue":"4","key":"15412_CR41","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11912-022-01224-0","volume":"24","author":"N Camarda","year":"2022","unstructured":"Camarda N, Trager MH, Yang J, et al. Vegf receptor inhibitor-induced hypertension: emerging mechanisms and clinical implications. Curr Oncol Rep. 2022;24(4):463\u201374.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"15412_CR42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00204-024-03874-4","volume":"99","author":"YX Du","year":"2025","unstructured":"Du YX, Yao W, Qiu H, et al. Hypertension toxicity of VEGFR-TKIs in cancer treatment: incidence, mechanisms, and management strategies. Arch Toxicol. 2025;99(1):67\u201381.","journal-title":"Arch Toxicol"},{"issue":"1","key":"15412_CR43","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11845-024-03863-7","volume":"194","author":"AM Alfaraheed","year":"2025","unstructured":"Alfaraheed AM, Alhumaidan AM, Alzaid AA, et al. The role of clinical pharmacist in the management of resistant hypertension. Ir J Med Sci. 2025;194(1):81\u20139.","journal-title":"Ir J Med Sci"},{"issue":"2","key":"15412_CR44","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4103\/jpbs.jpbs_1025_23","volume":"16","author":"JU Mohammed","year":"2024","unstructured":"Mohammed JU, Ahmed R, Khan S. Evaluation of the impact of a pharmacist-conducted hypertension clinic. J Pharm Bioallied Sci. 2024;16(2):79\u201385.","journal-title":"J Pharm Bioallied Sci"},{"issue":"2","key":"15412_CR45","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/bcp.15514","volume":"89","author":"EE Ayogu","year":"2023","unstructured":"Ayogu EE, Nduka SO, Ofoegbu TC, et al. Effectiveness of a pharmacist-led educational intervention on health outcomes in hypertension management at community pharmacies in nigeria: a two-arm parallel single-blind randomized controlled trial. Br J Clin Pharmacol. 2023;89(2):649\u201359.","journal-title":"Br J Clin Pharmacol"},{"key":"15412_CR46","doi-asserted-by":"publisher","first-page":"747650","DOI":"10.3389\/fmolb.2021.747650","volume":"8","author":"Y You","year":"2021","unstructured":"You Y, Gong Y, Wang H, et al. Activity of PD-1 inhibitor combined with anti-angiogenic therapy in advanced sarcoma: a single-center retrospective analysis. Front Mol Biosci. 2021;8:747650.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"15412_CR47","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1038\/s41598-023-30412-6","volume":"13","author":"Z Liu","year":"2023","unstructured":"Liu Z, Li F, Qu H, et al. Efficacy and safety of angiogenesis inhibitors plus immune checkpoint inhibitors in advanced soft tissue sarcoma: a real-world, single-center study. Sci Rep. 2023;13(1):3385.","journal-title":"Sci Rep."},{"issue":"5","key":"15412_CR48","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/cncr.22455","volume":"109","author":"S DuBois","year":"2007","unstructured":"DuBois S, Demetri G. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer. 2007;109(5):813\u20139.","journal-title":"Cancer"},{"issue":"6","key":"15412_CR49","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/pbc.22178","volume":"53","author":"J Bajpai","year":"2009","unstructured":"Bajpai J, Sharma M, Sreenivas V, et al. Vegf expression as a prognostic marker in osteosarcoma. Pediatr Blood Cancer. 2009;53(6):1035\u20139.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"15412_CR50","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s13018-019-1301-z","volume":"14","author":"H Wu","year":"2019","unstructured":"Wu H, Zhang J, Dai R, et al. Transferrin receptor-1 and VEGF are prognostic factors for osteosarcoma. J Orthop Surg Res. 2019;14(1):296.","journal-title":"J Orthop Surg Res"},{"issue":"3","key":"15412_CR51","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s10434-001-0260-9","volume":"8","author":"C Chao","year":"2001","unstructured":"Chao C, Al-Saleem T, Brooks JJ, et al. Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann Surg Oncol. 2001;8(3):260\u20137.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"15412_CR52","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.ajpath.2019.04.017","volume":"189","author":"BK Straub","year":"2019","unstructured":"Straub BK, Witzel HR, Pawella LM, et al. Perilipin 1 expression differentiates liposarcoma from other types of soft tissue sarcoma. Am J Pathol. 2019;189(8):1547\u201358.","journal-title":"Am J Pathol"},{"issue":"1","key":"15412_CR53","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41467-024-45306-y","volume":"15","author":"S Tang","year":"2024","unstructured":"Tang S, Wang Y, Luo R, et al. Proteomic characterization identifies clinically relevant subgroups of soft tissue sarcoma. Nat Commun. 2024;15(1):1381.","journal-title":"Nat Commun"},{"issue":"2","key":"15412_CR54","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/bjs.4398","volume":"91","author":"AJ Hayes","year":"2004","unstructured":"Hayes AJ, Mostyn-Jones A, Koban MU, et al. Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br J Surg. 2004;91(2):242\u20137.","journal-title":"Br J Surg"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15412-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15412-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15412-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:02:23Z","timestamp":1773403343000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15412-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15412"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15412-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"345"}}